Updated Jul 16, 2026
Pauwels Eric has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $4.88M.
Eric Pauwels serves as the Chief Business Officer at PTC Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for rare disorders. He has been involved in the company's strategic business initiatives and partnerships.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-12 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 17.6K | $75.00 | $1.32M |
| 2026-06-12 | PTCT | PTC THERAPEUTICS, INC. | M — Option exercise | 17.6K | $18.01 | $316K |
| 2026-06-12 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 3.7K | $75.00 | $278K |
| 2026-02-20 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 3.0K | $69.36 | $209K |
| 2026-01-12 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale [10b5-1] | 1.0K | $78.70 | $81K |
| 2026-01-12 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale [10b5-1] | 1.7K | $77.41 | $133K |
| 2026-01-12 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale [10b5-1] | 1.5K | $76.45 | $111K |
| 2026-01-12 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale [10b5-1] | 587 | $76.98 | $45K |
| 2026-01-12 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale [10b5-1] | 2.6K | $76.42 | $196K |
| 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 1.4K | $77.48 | $105K |
| 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 1.8K | $76.95 | $138K |
| 2025-09-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 1.2K | $56.86 | $71K |
| 2025-09-08 | PTCT | PTC THERAPEUTICS, INC. | M — Option exercise | 1.2K | $11.32 | $14K |
| 2025-09-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 1.2K | $56.85 | $70K |
| 2025-09-08 | PTCT | PTC THERAPEUTICS, INC. | M — Option exercise | 1.2K | $11.32 | $14K |
| 2025-09-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 2.4K | $56.92 | $137K |
| 2025-09-08 | PTCT | PTC THERAPEUTICS, INC. | M — Option exercise | 2.4K | $11.23 | $27K |
| 2025-09-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 3.7K | $56.92 | $211K |
| 2025-09-08 | PTCT | PTC THERAPEUTICS, INC. | M — Option exercise | 3.7K | $30.86 | $115K |
| 2025-09-08 | PTCT | PTC THERAPEUTICS, INC. | S — Open-market sale | 8.5K | $56.92 | $485K |
Eric Pauwels serves as the Chief Business Officer at PTC Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for rare disorders. He has been involved in the company's strategic business initiatives and partnerships.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 18 open-market sales ($4.88M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Pauwels Eric profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.